Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Vagistat-1

This article was originally published in The Tan Sheet

Executive Summary

Vagistat-1: Advertising for Bristol-Myers Squibb's one-day vaginal yeast infection treatment is being handled by Wells Rich Greene BDDP (New York City). The tioconazole 6.5% OTC treatment, approved by FDA Feb. 11, is being shipped on a limited basis, the company says. A professional "coming soon" ad for Vagistat-1 appearing in the April 17 edition of the New England Journal of Medicine highlights the treatment's "one dose...broad-spectrum activity" and notes that Vagistat-1 will be "available this spring"...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086937

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel